{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:13:15Z","timestamp":1769047995776,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1038\/leu.2017.258","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T06:40:25Z","timestamp":1504248025000},"page":"719-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pomalidomide\u2013dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial"],"prefix":"10.1038","volume":"32","author":[{"given":"S","family":"Ailawadhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J R","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B R","family":"LaPlant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K M","family":"Laumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"S","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P L","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F K","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S V","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S R","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A K","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R A","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W I","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C B","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R S","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Lust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A A","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Q","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"key":"BFleu2017258_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621\u2013631.","journal-title":"N Engl J Med"},{"key":"BFleu2017258_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142\u2013152.","journal-title":"N Engl J Med"},{"key":"BFleu2017258_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 1319\u20131331.","journal-title":"N Engl J Med"},{"key":"BFleu2017258_CR4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grazsko N, Bahlis NJ, Hansson M, Pour L et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 374: 1621\u20131634.","journal-title":"N Engl J Med"},{"key":"BFleu2017258_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 754\u2013766.","journal-title":"N Engl J Med"},{"key":"BFleu2017258_CR6","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol 2015; 33: 3459\u20133466.","journal-title":"J Clin Oncol"},{"key":"BFleu2017258_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11899-013-0173-2","volume":"8","author":"JP Meadows","year":"2013","unstructured":"Meadows JP, Mark TM . Management of double-refractory multiple myeloma. Curr Hematol Malig Rep 2013; 8: 253\u2013260.","journal-title":"Curr Hematol Malig Rep"},{"key":"BFleu2017258_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3324\/haematol.2016.148882","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A . Treatment of relapsed and refractory multiple myeloma. Haematologica 2016; 101: 995.","journal-title":"Haematologica"},{"key":"BFleu2017258_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149\u2013157.","journal-title":"Leukemia"},{"key":"BFleu2017258_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07013.x","volume":"141","author":"MJ Streetly","year":"2008","unstructured":"Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA . Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008; 141: 41\u201351.","journal-title":"Br J Haematol"},{"key":"BFleu2017258_CR11","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014; 123: 1826\u20131832.","journal-title":"Blood"},{"key":"BFleu2017258_CR12","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","volume":"27","author":"MQ Lacy","year":"2009","unstructured":"Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008\u20135014.","journal-title":"J Clin Oncol"},{"key":"BFleu2017258_CR13","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","volume":"118","author":"MQ Lacy","year":"2011","unstructured":"Lacy MQ, Alfred JB, Gertz MA, Hayman, Short KD, Buadi F et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011; 118: 2970\u20132975.","journal-title":"Blood"},{"key":"BFleu2017258_CR14","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","volume":"121","author":"X Leleu","year":"2013","unstructured":"Leleu X, Attal M, Arnulf B, Moreau P, Traulie C, Marit G et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood 2013; 121: 1968\u20131975.","journal-title":"Blood"},{"key":"BFleu2017258_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","volume":"128","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Ramonodo F et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood 2016; 128: 497\u2013503.","journal-title":"Blood"},{"key":"BFleu2017258_CR16","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1080\/10428194.2016.1177181","volume":"57","author":"DS Siegel","year":"2016","unstructured":"Siegel DS, Weisel KC, Dimopoulos MS, Baz R, Richardson P, Delforge M et al. Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma 2016; 57: 2833\u20132838.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2017258_CR17","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/leu.2010.190","volume":"24","author":"MQ Lacy","year":"2010","unstructured":"Lacy MQ, Hayman DR, Gertz MA, Short KD, Dispenzieri A, Kumar S et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24: 1934\u20131939.","journal-title":"Leukemia"},{"key":"BFleu2017258_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV . Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3\u20139.","journal-title":"Leukemia"},{"key":"BFleu2017258_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Duadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013; 88: 360\u2013376.","journal-title":"Mayo Clin Proc"},{"key":"BFleu2017258_CR20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 1055\u20131066.","journal-title":"Lancet Oncol"},{"key":"BFleu2017258_CR21","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551\u20131560.","journal-title":"Lancet"},{"key":"BFleu2017258_CR22","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.3324\/haematol.2014.112557","volume":"100","author":"KW Song","year":"2015","unstructured":"Song KW, Dimopoulas MA, Weisel KC, Moreau P, Palumbo A, Belch A et al. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and\/or refractory multiple myeloma. Haematologica 2015; 100: e63\u2013e67.","journal-title":"Haematologica"},{"key":"BFleu2017258_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","volume":"15","author":"K Weisel","year":"2015","unstructured":"Weisel K, Dimopoulos M, Song KW, Moreau P, Palumbo A, Belch A et al. Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed\/refractory patients with multiple myeloma enrolled in the MM-003 Randomized Phase III Trial. Clin Lymphoma Myeloma Leuk 2015; 15: 519\u2013530.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017258","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:09:13Z","timestamp":1684433353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["BFleu2017258"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.258","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,1]]},"assertion":[{"value":"9 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SA has served on advisory board for Amgen, Novartis, Takeda and Pharmacyclics, and receives research funding from Pharmacyclics; JRM receives research funding from Abbvie, Celgene and Sanofi; SK receives research funding from Takeda, Celgene, Novartis, Abbvie, Janssen and Roche; DD receives research funding from Karyopharm, Amgen and Takeda; PLB receives research funding from Novartis, Constellation and Mundipharma, and has served on advisory board for Incyte, Janssen, Adaptive Bioscience and Juno Therapeutics; MAG receives research funding from Celgene, Janssen, Prothena, Ionis, Alnylam and Sandoz; PK has served on advisory board for Sanofi-Genzyme and receives research funding from Takeda, Celgene and Amgen; AKS receives research funding from Celgene, Amgen, Bristol Myers Squibb and Janssen; AD receives research funding from Celgene, Millennium, Pfizer and Janssen, and has received travel grant from Pfizer and Prothena; CBR receives research funding from Celgene, Novartis, Takeda and BMS; YL receives research funding from Janssen; ACK receives research funding from Pharmacyclics; MQL receives research funding from Celgene. The remaining authors declare no conflict of interest. Funding from CA 186781 was utilized to support investigator effort in data analysis and manuscript preparation for this trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}